{"id":1850,"date":"2024-06-27T08:52:51","date_gmt":"2024-06-27T15:52:51","guid":{"rendered":"https:\/\/blogschapman.wpenginepowered.com\/pharmacy\/2024\/06\/27\/national-institute-on-aging-awards-grant-to-dr-rachita-sumbria-for-alzheimers-disease-theraputics\/"},"modified":"2024-06-27T08:52:51","modified_gmt":"2024-06-27T15:52:51","slug":"national-institute-on-aging-awards-grant-to-dr-rachita-sumbria-for-alzheimers-disease-theraputics","status":"publish","type":"post","link":"https:\/\/blogs.chapman.edu\/pharmacy\/2024\/06\/27\/national-institute-on-aging-awards-grant-to-dr-rachita-sumbria-for-alzheimers-disease-theraputics\/","title":{"rendered":"National Institute on Aging Awards Grant to Dr. Rachita Sumbria for Alzheimer&#039;s Disease Therapeutics"},"content":{"rendered":"<div class=\"flex flex-grow flex-col max-w-full\">\n<div class=\"min-h-[20px] text-message flex flex-col items-start whitespace-pre-wrap break-words [.text-message+&amp;]:mt-5 juice:w-full juice:items-end overflow-x-auto gap-2\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"143b5332-e3b1-4ef3-893b-b19c6f47b775\">\n<div class=\"flex w-full flex-col gap-1 juice:empty:hidden juice:first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p><a href=\"https:\/\/blogs.chapman.edu\/pharmacy\/wp-content\/uploads\/sites\/65\/2024\/06\/rachita-sumbria.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-1858 alignleft\" src=\"https:\/\/blogs.chapman.edu\/pharmacy\/wp-content\/uploads\/sites\/65\/2024\/06\/rachita-sumbria.jpg\" alt=\"\" width=\"235\" height=\"240\"><\/a>Dr. <a href=\"https:\/\/www.chapman.edu\/our-faculty\/rachita-sumbria\" target=\"_blank\" rel=\"noopener noreferrer\">Rachita Sumbria<\/a>, an associate professor at Chapman University&#8217;s <a href=\"https:\/\/www.chapman.edu\/pharmacy\/\">School of Pharmacy<\/a>, has been awarded an NIH R01 grant from the National Institute on Aging, receiving $1.71 million over the next 5 years for research on Alzheimer\u2019s disease (AD) therapeutics. This project is founded on data from her lab&#8217;s earlier successes in modifying erythropoietin (EPO) to cross the blood-brain barrier (BBB) with promising results in treating AD.<\/p>\n<p>EPO&#8217;s ability to modulate AD-related pathways and its neuroprotective effects provide the rationale for its development, although its limited BBB penetration and hematopoietic side effects pose challenges. The proposed solution involves fusing EPO with a monoclonal antibody (MAb) against the transferrin receptor (TfR) to facilitate BBB penetration and reduce side effects.<\/p>\n<p>The funds will be used to conduct dose-escalation and safety studies in various AD models, and to investigate the molecular pathways modulated by TfRMAb-EPO, building on prior NIH R21-funded proof-of-concept studies. Preliminary data indicate that this BBB-penetrating EPO has better therapeutic and hematologic indices than EPO alone. EPO\u2019s neuroprotective effects and ability to modulate AD-related pathways justify its development, despite challenges like limited BBB penetration and hematopoietic side effects. The findings may establish a clinically feasible method for sustainable EPO delivery to the AD brain.<\/p>\n<p><em>The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.<\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Rachita Sumbria, an associate professor at Chapman University&#8217;s School of Pharmacy, has been awarded an NIH R01 grant from [&hellip;]<\/p>\n","protected":false},"author":4726,"featured_media":1856,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"custom_author_name":"","chapman_pin_hero_slider":"","footnotes":""},"categories":[185,405,174,33,37,53],"tags":[1739,1740,1741,1742,1743,1744,1117,1745,1746,1747,1748,1749,1408,1750,1751,1752,1753,1754,1755,1756,1757,1758,1759,1760,1761,1762,1763,1764,861,1765,1766,1767,1768,1769,1665,1770,1771,1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784,1785,1786],"class_list":["post-1850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-awards","category-faculty","category-grants","category-pharmacy-industry","category-publications","category-research","tag-1-71-million","tag-5-years","tag-ad-mouse-models","tag-alzheimers-disease","tag-alzheimers-disease-therapeutics","tag-amyloidosis","tag-blood-brain-barrier","tag-blood-brain-barrier-bbb-penetrating-erythropoietin","tag-clinical-feasibility","tag-cognitive-function","tag-disease-modifying-treatment-for-ad","tag-dose-escalation-studies","tag-dr-rachita-sumbria","tag-drug-delivery-systems","tag-efficacy","tag-erythropoietin-epo","tag-facilitate-bbb-penetration","tag-fusing-epo","tag-hematologic-indices","tag-hematopoietic-side-effects","tag-limited-bbb-penetration","tag-lower-doses","tag-mechanistic-insights","tag-modulate-ad-related-pathways","tag-molecular-pathways","tag-monoclonal-antibody-mab","tag-mouse-models","tag-national-institute-on-aging","tag-national-institutes-of-health","tag-neuroprotective-effects","tag-nih-r01-grant","tag-pathological-brain-a42","tag-pi","tag-preclinical-development","tag-preliminary-data","tag-r21-funded-proof-of-concept-studies","tag-reduce-side-effects","tag-safety-profile","tag-safety-studies","tag-specific-aims","tag-sumbria-lab","tag-sustainable-epo-delivery","tag-synaptophysin","tag-tauopathy","tag-tfrmab-epo","tag-tfrmab-epo-fusion","tag-therapeutic-for-alzheimers-disease-ad","tag-therapeutic-indices","tag-therapeutic-range","tag-third-active-r01","tag-tolerable-doses","tag-transferrin-receptor-tfr"],"_links":{"self":[{"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/posts\/1850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/users\/4726"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/comments?post=1850"}],"version-history":[{"count":0,"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/posts\/1850\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/media\/1856"}],"wp:attachment":[{"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/media?parent=1850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/categories?post=1850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.chapman.edu\/pharmacy\/wp-json\/wp\/v2\/tags?post=1850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}